Cell & tissue research
SS-31 / Elamipretide
What is it?
SS-31 is a development name for elamipretide, a synthetic tetrapeptide studied for interactions with mitochondrial membranes. Its research context concerns mitochondrial function and disease, rather than a generic energy or anti-ageing claim.
How it is studied
Elamipretide interacts with cardiolipin, a lipid important to the organisation of the inner mitochondrial membrane. This provides a rationale for investigating mitochondrial disorders. Biological targeting alone cannot predict clinical benefit across unrelated conditions.
What the evidence shows
The FDA granted accelerated approval to the defined elamipretide medicine Forzinity in 2025 to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. Accelerated approval requires further confirmatory evidence. This is a narrow disease-specific context, not approval of supplier SS-31 vials.
Limitations & safety context
A research entry labelled 10 mg or 50 mg is not established as the approved medicine. The official formulation and safety information concern a specific product and patient population. The attachment does not establish clinical equivalence, sterility, identity or suitability for human administration.
Listed specifications
| Reference | Listed contents |
|---|---|
| 2S10 | 10 mg |
| 2S50 | 50 mg |
Source-document quantities, not doses or a confirmation of stock. Identity, purity, component composition and suitability require separate documentation.
Research information only. No dosing, administration or treatment advice.